Abbisko Cayman (2256.HK) - The Pipeline Lacks Investment Value, Leading to Valuation Collapse
There are "obvious flaws" on Abbiskoās pipeline and targets, leading to limited investment value and gloomy commercialization outlook. So, share...
339 Views
China Healthcare Weekly (March.3) - TCM New Policy, Pfizer to Acquire Seagen, Haohai Biological
New favorable policy for TCM industry was released. We analyzed our top picks. Pfizer is in talks to acquire Seagen, but we're conservative about...
714 Views
China Healthcare Weekly (Feb.3)- CanSino, Blood Products Shortage, Don't Be Greedy in Front of Rally
Contradiction between blood products supply and demand is intensifying. Cansino plans to IPO in Swiss -We see upside potential in...
592 Views
Gushengtang IPO Trading - Priced at Top End with Lukewarm Subscription Rates
Gushengtang (GUS HK) raised around US$104m after pricing its IPO at HKD29.0/share, at the top end of the IPO price range.
610 Views
ECM Weekly (17th October 2021) - SG Lottery, GQG, Judo Bank, Vulcan Steel, Biocytogen, Kakao Pay
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
620 Views